Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Breast Neoplasms 665Neoplasms 585Colorectal Neoplasms 291Carcinoma, Non-Small-Cell Lung 289Prostatic Neoplasms 277Lung Neoplasms 217Melanoma 159Multiple Myeloma 149Neoplasm Metastasis 145Head and Neck Neoplasms 143Pancreatic Neoplasms 139Ovarian Neoplasms 129Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 121Brain Neoplasms 111Squamous Cell Carcinoma of Head and Neck 109Colonic Neoplasms 109Uterine Cervical Neoplasms 106Stomach Neoplasms 102Recurrence 101Lymphoma 100Glioblastoma 90Lymphoma, Non-Hodgkin 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 78Hematologic Neoplasms 78Lymphoma, Follicular 77Urinary Bladder Neoplasms 76Parkinson Disease 4, Autosomal Dominant Lewy Body 74Glioma 72Sarcoma 70

Interventions

durvalumab 1adavosertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumours × 1 year × Clear all
NCT02617277 2026-03-04

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
56 enrolled
Other solid neoplasm

Advanced Solid Tumours

NCT05508334 2025-12-22

A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

RemeGen Co., Ltd.

Phase 1/2 Completed
41 enrolled
Other solid neoplasm

Advanced Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡